Author:
Miles Brittany,Chacko Jay,Zaidan Mohammed
Reference20 articles.
1. Google News. Coronavirus (COVID-19). (2022). Accessed: September 7, 2022: https://news.google.com/covid19/map.
2. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area;Richardson S;JAMA,2020
3. Food and Drug Administration. Elexacaftor/ivacaftor/tezacaftor. (2019). Accessed: July 5, 2022: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-elexacaftor/ivacaftor/tezacaftor.
4. Development of elexacaftor - tezacaftor - ivacaftor: highly effective CFTR modulation for the majority of people with cystic fibrosis;Middleton PG;Expert Rev Respir Med,2021
5. A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy;Zaher A;Cureus,2021